The director option cancellations are non-cash and routine; the 140M unquoted option grant adds potential future dilution but is restricted and unquoted. Monitor for any subsequent ASX announcements regarding exercise or conversion of these options, which could signal insider sentiment or capital needs.
Price Chart
Executive Summary
Radiopharm Theranostics filed a 6-K reporting that four directors (Bruce Goodwin, Ian Turner, Paul Hopper, Riccardo Canevari) each had listed options cancelled for nil consideration on October 16, 2026, and that 140,028,000 unquoted employee incentive options (RADAN) were issued on October 19, 2026, including 30,887,000 to KMP Dimitris Voliotis. The director option cancellations are routine administrative events with no cash consideration, while the large employee option grant adds potential future dilution but is unquoted and restricted.
Key Facts
- Four directors had listed options cancelled on October 16, 2026 for nil consideration: Bruce Goodwin (1,111,111), Ian Turner (1,111,111), Paul Hopper (1,111,111), Riccardo Canevari (1,555,556).
- 140,028,000 unquoted options (RADAN) were issued on October 19, 2026 under the employee incentive scheme, of which 30,887,000 went to KMP Dimitris Voliotis.
- The new options are unquoted and subject to transfer restrictions until they end.
- No financial figures (revenue, earnings, cash) were reported in this filing.
Financial Impact
No cash consideration involved in director option cancellations; 140,028,000 unquoted options issued with no stated exercise price or market value.
Risk Factors
- Potential future dilution if the 140,028,000 unquoted options are exercised or converted.
- No operational or financial updates in this filing — limited visibility into company performance.
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-110813 |
| Document: ea030912301ex99-2.htm | 0001213900-26-110813 |
| Document: ea0309123-6k_radiopharm.htm | 0001213900-26-110813 |
| Document: 0001213900-26-110813-index-headers.html | 0001213900-26-110813 |
| Document: 0001213900-26-110813-index.html | 0001213900-26-110813 |
| Document: 0001213900-26-110813.txt | 0001213900-26-110813 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | — | awaiting T+5 | — | — |
Oct 20, 2026 6d ago | 6-K | $0.9900 | awaiting T+5 | — | $0.9600 (−3.03%) |
Oct 14, 2026 11d ago | SC 13G | $1.08 $0.9500 | ▼ −12.04% | ▼ −11.02% | $0.9600 (−11.11%) |
Oct 5, 2026 21d ago | 6-K | $1.27 $1.11 | ▼ −12.60% | ▼ −13.02% | $0.9600 (−24.41%) |
Oct 1, 2026 25d ago | 6-K | $1.48 $1.11 | ▼ −25.00% | ▼ −26.30% | $0.9600 (−35.14%) |
Sep 30, 2026 26d ago | 6-K | $1.62 $1.15 | ▼ −29.01% | ▼ −30.93% | $0.9600 (−40.74%) |
Sep 24, 2026 4w ago | EFFECT | $1.57 $1.48 | ▲ +5.85% | ▲ +5.43% | $0.9600 (+38.93%) |
Sep 22, 2026 4w ago | 6-K | $1.65 $1.52 | ▼ −7.88% | ▼ −6.69% | $0.9600 (−41.82%) |
Sep 14, 2026 6w ago | 6-K | $2.01 $1.61 | ▼ −19.90% | ▼ −20.01% | $0.9600 (−52.24%) |
Sep 11, 2026 6w ago | 6-K | $1.98 $1.65 | ▼ −16.67% | ▼ −16.45% | $0.9600 (−51.52%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers